The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home.

Risdiplam (Evrysdi) is a liquid medicine intended for daily use that was developed by Roche subsidiary Genentech in partnership with the SMA Foundation and South Plainfield, NJ-based PTC Therapeutics (NASDAQ: PTCT).

Regulators OK’d the drug, intended for daily administration via mouth or feeding tube, for patients with all forms of the disease starting at two months of age. In a prepared statement the FDA’s Billy Dunn, who heads its neuroscience unit, highlighted the dosing advantage.

“Evrysdi is the first drug for this disease… Read more »